000165716 001__ 165716
000165716 005__ 20260113234335.0
000165716 0247_ $$2doi$$a10.1002/cpt.3132
000165716 0248_ $$2sideral$$a136084
000165716 037__ $$aART-2023-136084
000165716 041__ $$aeng
000165716 100__ $$aDonker, Erik M.
000165716 245__ $$aThe European list of key medicines for medical education: a modified Delphi study
000165716 260__ $$c2023
000165716 5060_ $$aAccess copy available to the general public$$fUnrestricted
000165716 5203_ $$aRational prescribing is essential for the quality of health care. However, many final-year medical students and junior doctors lack prescribing competence to perform this task. The availability of a list of medicines that a junior doctor working in Europe should be able to independently prescribe safely and effectively without supervision could support and harmonize teaching and training in clinical pharmacology and therapeutics (CPT) in Europe. Therefore, our aim was to achieve consensus on such a list of medicines that are widely accessible in Europe. For this, we used a modified Delphi study method consisting of three parts. In part one, we created an initial list based on a literature search. In part two, a group of 64 coordinators in CPT education, selected via the Network of Teachers in Pharmacotherapy of the European Association for Clinical Pharmacology and Therapeutics, evaluated the accessibility of each medicine in his or her country, and provided a diverse group of experts willing to participate in the Delphi part. In part three, 463 experts from 24 European countries were invited to participate in a 2-round Delphi study. In total, 187 experts (40%) from 24 countries completed both rounds and evaluated 416 medicines, 98 of which were included in the final list. The top three Anatomical Therapeutic Chemical code groups were (1) cardiovascular system (n = 23), (2) anti-infective (n = 21), and (3) musculoskeletal system (n = 11). This European List of Key Medicines for Medical Education could be a starting point for country-specific lists and could be used for the training and assessment of CPT.
000165716 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttps://creativecommons.org/licenses/by-nc/4.0/deed.es
000165716 590__ $$a6.3$$b2023
000165716 591__ $$aPHARMACOLOGY & PHARMACY$$b25 / 354 = 0.071$$c2023$$dQ1$$eT1
000165716 592__ $$a1.988$$b2023
000165716 593__ $$aPharmacology (medical)$$c2023$$dQ1
000165716 593__ $$aPharmacology$$c2023$$dQ1
000165716 594__ $$a12.7$$b2023
000165716 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000165716 700__ $$aSpitaleri Timpone, Pietro... [et al.]
000165716 700__ $$aNetwork of Teachers in Pharmacotherapy
000165716 700__ $$0(orcid)0000-0002-8222-1418$$aBernal, María Luisa$$uUniversidad de Zaragoza
000165716 700__ $$0(orcid)0000-0003-2361-9941$$aPérez Calvo, Juan Ignacio$$uUniversidad de Zaragoza
000165716 700__ $$0(orcid)0000-0003-2153-0417$$aAvedillo Salas, Ana$$uUniversidad de Zaragoza
000165716 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000165716 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000165716 773__ $$g115, 3 (2023), 515-524$$pClin. pharmacol. ther.$$tCLINICAL PHARMACOLOGY & THERAPEUTICS$$x0009-9236
000165716 8564_ $$s439176$$uhttps://zaguan.unizar.es/record/165716/files/texto_completo.pdf$$yVersión publicada
000165716 8564_ $$s2618465$$uhttps://zaguan.unizar.es/record/165716/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000165716 909CO $$ooai:zaguan.unizar.es:165716$$particulos$$pdriver
000165716 951__ $$a2026-01-13-22:06:47
000165716 980__ $$aARTICLE